Chinook Therapeutics Inc (NASDAQ:KDNY)

19.48
Delayed Data
As of Sep 29
 -0.27 / -1.37%
Today’s Change
10.48
Today|||52-Week Range
23.86
+19.44%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$1.2B

Company Description

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Contact Information

Chinook Therapeutics, Inc.
400 Fairview Avenue North
Seattle Washington 98109
P:(206) 485-7241
Investor Relations:

Employees

Shareholders

Other institutional47.43%
Mutual fund holders17.91%
Individual stakeholders16.28%

Top Executives

Eric L. DobmeierChairman, President & Chief Executive Officer
Tom FrohlichChief Operating Officer
Eric Hands Claude BjerkholtChief Financial Officer
Andrew KingChief Scientific Officer
Kirk D. SchumacherSenior Vice President & General Counsel